טוען...
Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
BACKGROUND: Pirfenidone was approved by the European Medicines Agency and introduced in most European countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months with respect to targe...
שמור ב:
| הוצא לאור ב: | Eur Clin Respir J |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Co-Action Publishing
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5018656/ https://ncbi.nlm.nih.gov/pubmed/27616539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/ecrj.v3.32608 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|